{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T21:49:54Z","timestamp":1774475394647,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"major chronic non-communicable diseases prevention and control research","award":["2018YFC1312801"],"award-info":[{"award-number":["2018YFC1312801"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Coronary artery stenosis induces heart diseases including acute coronary syndrome (ACS). Some studies reported the ceramide species are associated with the ACS and major adverse cardia and cerebrovascular events (MACE). However, few studies investigated the association between plasma ceramide levels and the severity of stenosis, together with the onset of diseases. This aim of the present study was to investigate the association betweencertain ceramide species, coronary artery stenosis and acute coronary syndrome.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Five hundred fifty-three patients with definite or suspected CAD were recruited and received angiography. Subjects were assigned into 4 groups according to the severity of coronary artery stenosis. The measurements of 4 plasma ceramide species, namely, Cer (d18:1\/16:0), Cer (d18:1\/18:0), Cer (d18:1\/24:1), Cer (d18:1\/24:0) were carried out by Liquid chromatography-tandem mass spectrometry (LC-MS\/MS) and the ratio of Cer (d18:1\/16:0), Cer (d18:1\/18:0) and Cer (d18:1\/24:1) to Cer (18:1\/24:0), respectively, were calculated as index to evaluate the association between plasma ceramides levels and coronary artery stenosis. Multiple logistic regression analysis was used to establish the prognostic model for the prediction of ACS risk.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>After the adjustment by multiple clinical risk factors including age, gender, pre-existing myocardial\/cerebral infarction, hemoglobin A1c% (HbA1c%), smoking and the diagnosis during index hospitalization, multiple logistic regression analysis showed that the high ratio of Cer (d18:1\/24:1) to Cer (d18:1\/24:0), female gender, HbA1c%, unstable angina (UAP) and acute myocardial infarction (AMI) diagnosis (compared with atherosclerosis) during index hospitalization were associated with more severe coronary artery stenosis. Furthermore, the prognostic model was established after adjustment of risk factors and the area under curve (AUC) of receiver operating characteristics (ROC) for the prognostic model was 0.732 and 95% CI was 0.642\u20130.822.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The severity of coronary artery stenosis is associated with high ratio of Cer (d18:1\/24:1) to Cer (d18:1\/24:0), female gender, HbA1c% and AMI. Although the reported prognostic model showed a good discrimination, further investigation on long term MACE is needed to evaluate the role of ceramide for the prediction of MACE risk.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12944-020-01329-0","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T08:02:38Z","timestamp":1593072158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Association between ceramides and coronary artery stenosis in patients with coronary artery disease"],"prefix":"10.1186","volume":"19","author":[{"given":"Chenchen","family":"Tu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-1148","authenticated-orcid":false,"given":"Yong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"issue":"12","key":"1329_CR1","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1161\/01.ATV.20.12.2614","volume":"20","author":"XC Jiang","year":"2000","unstructured":"Jiang XC, Paultre F, Pearson TA, Reed RG. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20(12):2614\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1329_CR2","first-page":"167","volume":"68","author":"SG Worthley","year":"2001","unstructured":"Worthley SG, Osende JI, Helft G, Badimon JJ, Fuster V. Coronary artery disease: pathogenesis and acute coronary syndromes. Mt Sinai J Med. 2001;68(3):167\u201381.","journal-title":"Mt Sinai J Med"},{"issue":"2\u20133","key":"1329_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1388-1981(00)00042-1","volume":"1485","author":"A Huwiler","year":"2000","unstructured":"Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta. 2000;1485(2\u20133):63\u201399.","journal-title":"Biochim Biophys Acta"},{"key":"1329_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2016.09.028","volume":"370","author":"Y Xing","year":"2016","unstructured":"Xing Y, Tang Y, Zhao L, Wang Q, Qin W, Ji X, et al. Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson's disease dementia. J Neurol Sci. 2016;370:82\u20137.","journal-title":"J Neurol Sci"},{"key":"1329_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jad.2017.02.008","volume":"213","author":"A Dinoff","year":"2017","unstructured":"Dinoff A, Herrmann N, Lanct\u00f4t KL. Ceramides and depression: a systematic review. J Affect Disord. 2017;213:35\u201343.","journal-title":"J Affect Disord"},{"issue":"19","key":"1329_CR6","first-page":"30091","volume":"S1262\u20133636","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Altomari A, Lunardi G, Bonapace S, Lippi G, Bonnet F, et al. Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes. Diabetes Metab. 2019;S1262\u20133636(19):30091\u20136.","journal-title":"Diabetes Metab"},{"issue":"22","key":"1329_CR7","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.1997.03540460039030","volume":"277","author":"IM Graham","year":"1997","unstructured":"Graham IM, Daly LE, Refsum HM, Robinson K, Brattstr\u00f6m LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European concerted action project. JAMA. 1997;277(22):1775\u201381.","journal-title":"JAMA"},{"issue":"9","key":"1329_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s11745-006-5041-6","volume":"41","author":"I Ichi","year":"2006","unstructured":"Ichi I, Nakahara K, Miyashita Y, Hidaka A, Kutsukake S, Inoue K, et al. Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids. 2006;41(9):859\u201363.","journal-title":"Lipids."},{"issue":"2","key":"1329_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.atherosclerosis.2015.10.022","volume":"243","author":"JM Cheng","year":"2015","unstructured":"Cheng JM, Suoniemi M, Kardys I, Vihervaara T, de Boer SP, Akkerhuis KM, et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2015;243(2):560\u20136.","journal-title":"Atherosclerosis."},{"issue":"25","key":"1329_CR10","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","volume":"37","author":"EK LaaksonenR","year":"2016","unstructured":"LaaksonenR EK. Sysi-AhoM, HilvoM, VihervaaraT, KauhanenD, et al. plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37(25):1967\u201376.","journal-title":"Eur Heart J"},{"issue":"12","key":"1329_CR11","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1161\/ATVBAHA.116.307497","volume":"36","author":"AS Havulinna","year":"2016","unstructured":"Havulinna AS, Sysi-Aho M, Hilvo M, Kauhanen D, Hurme R, Ekroos K, et al. Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort. Arterioscler Thromb Vasc Biol. 2016;36(12):2424\u201330.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"1329_CR12","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1161\/CIRCULATIONAHA.116.024261","volume":"135","author":"DD Wang","year":"2017","unstructured":"Wang DD, Toledo E, Hruby A, Rosner BA, Willett WC, Sun Q, et al. Plasma ceramides Mediterranean diet and incident cardiovascular disease in the PREDIMED trial (Prevenci\u00f3n con Dieta Mediterr\u00e1nea). Circulation. 2017;135(21):2028\u201340.","journal-title":"Circulation."},{"issue":"9","key":"1329_CR13","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1194\/jlr.P081281","volume":"59","author":"S Anroedh","year":"2018","unstructured":"Anroedh S, Hilvo M, Akkerhuis KM, Kauhanen D, Koistinen K, Oemrawsingh R, et al. Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. J Lipid Res. 2018;59(9):1729\u201337.","journal-title":"J Lipid Res"},{"issue":"12","key":"1329_CR14","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1161\/ATVBAHA.118.311927","volume":"38","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Bonapace S, Lunardi G, Salgarello M, Dugo C, Gori S, et al. Association of Plasma Ceramides with myocardial perfusion in patients with coronary artery disease undergoing stress myocardial perfusion scintigraphy. Arterioscler Thromb Vasc Biol. 2018;38(12):2854\u201361.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"25","key":"1329_CR15","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","volume":"37","author":"R Laaksonen","year":"2016","unstructured":"Laaksonen R, Ekroos K, Sysi-Aho M, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37(25):1967\u201376.","journal-title":"Eur Heart J"},{"key":"1329_CR16","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/ATVBAHA.118.311199","volume":"38","author":"JW Meeusen","year":"2018","unstructured":"Meeusen JW, Donato LJ, Bryant SC, Baudhuin LM, Berger PB, Jaffe AS. Plasma ceramides: a novel predictor of major adverse cardiovascular events after coronary angiography. Arterioscler Thromb Vasc Biol. 2018;38:1933\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1329_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37:267\u2013315.","journal-title":"Eur Heart J"},{"key":"1329_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119\u201377.","journal-title":"Eur Heart J"},{"key":"1329_CR19","first-page":"1","volume":"00","author":"J Knuuti","year":"2019","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;00:1\u201371.","journal-title":"Eur Heart J"},{"issue":"2","key":"1329_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jacbts.2017.12.005","volume":"3","author":"LP de Carvalho","year":"2018","unstructured":"de Carvalho LP, Tan SH, Ow GS, Tang Z, Ching J, Kovalik JP, et al. Plasma ceramides as prognostic biomarkers and their arterial and myocardial tissue correlates in acute myocardial infarction. JACC Basic Transl Sci. 2018;3(2):163\u201375.","journal-title":"JACC Basic Transl Sci"},{"issue":"39","key":"1329_CR21","doi-asserted-by":"publisher","first-page":"26509","DOI":"10.1074\/jbc.M801597200","volume":"283","author":"J Jin","year":"2008","unstructured":"Jin J, Hou Q, Mullen TD, Zeidan YH, Bielawski J, Kraveka JM, et al. Ceramide generated by sphingomyelin hydrolysis and the salvage pathway is involved in hypoxia\/reoxygenation-induced Bax redistribution to mitochondria in NT-2 cells. J Biol Chem. 2008;283(39):26509\u201317.","journal-title":"J Biol Chem"},{"issue":"3","key":"1329_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/FJC.0b013e31819b52d5","volume":"53","author":"SA Novgorodov","year":"2009","unstructured":"Novgorodov SA, Gudz TI. Ceramide and mitochondria in ischemia\/reperfusion. J Cardiovasc Pharmacol. 2009;53(3):198\u2013208.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"1329_CR23","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.bcp.2010.05.006","volume":"80","author":"I Syed","year":"2010","unstructured":"Syed I, Jayaram B, Subasinghe W, Kowluru A. Tiam1\/Racsignaling pathway mediates palmitate-induced, ceramide-sensitive generation of superoxides and lipid peroxides and the loss of mitochondrial membrane potential in pancreatic beta-cells. Biochem Pharmacol. 2010;80(6):874\u201383.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1329_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2012.08.041","volume":"226","author":"T Hornemann","year":"2013","unstructured":"Hornemann T, Worgall TS. Sphingolipids and atherosclerosis. Atherosclerosis. 2013;226(1):16\u201328.","journal-title":"Atherosclerosis."},{"issue":"6","key":"1329_CR25","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1161\/ATVBAHA.116.305675","volume":"36","author":"A Edsfeldt","year":"2016","unstructured":"Edsfeldt A, Duner P, Stahlman M, Mollet IG, Asciutto G, Grufman H, et al. Sphingolipids contribute to human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol. 2016;36(6):1132\u201340.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1329_CR26","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1096\/fj.201700300R","volume":"32","author":"BA Law","year":"2018","unstructured":"Law BA, Liao X, Moore KS, Southard A, Roddy P, Ji R. Ea al. Lipotoxic very-long-chain ceramides cause mitochondrial dysfunction, oxidative stress, and cell death in cardiomyocytes. FASEB J. 2018;32(3):1403\u201316.","journal-title":"FASEB J"},{"issue":"20","key":"1329_CR27","first-page":"30052","volume":"S0363-0188","author":"JG Escalon","year":"2020","unstructured":"Escalon JG, Bang TJ, Broncano J, Vargas D. Myocardial infarction with Normal coronary arteries (MINCA): potential etiologies, mimics and imaging findings. Curr Probl Diagn Radiol. 2020;S0363-0188(20):30052.","journal-title":"Curr Probl Diagn Radiol"},{"issue":"1","key":"1329_CR28","first-page":"20","volume":"25","author":"J Parnham","year":"2018","unstructured":"Parnham J, Geisslinger MJ, Schiffmann G. Susanne. Ceramides as novel disease biomarkers. Trends Mol Med. 2018;25(1):20\u201332.","journal-title":"Trends Mol Med"},{"issue":"2","key":"1329_CR29","first-page":"1","volume":"46","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Bonapace S, Lunardi G, Canali G, Dugo C, Vinco G, et al. Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronaryangiography. Diabetes Metab. 2019;46(2):1\u20138.","journal-title":"Diabetes Metab"},{"key":"1329_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2020.04.008","volume":"1","author":"WL Pan","year":"2020","unstructured":"Pan WL, Sun M, Wu JJ, Dong H, Liu JX, Gao R, et al. Relationship between elevated plasma ceramides and plaque rupture in patients with ST-segment elevation myocardial infarction. Atherosclerosis. 2020;1:8\u201314.","journal-title":"Atherosclerosis."},{"issue":"1","key":"1329_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.18632\/aging.101719","volume":"11","author":"V Vezella","year":"2019","unstructured":"Vezella V, Basit A, Piras F, Realini N, Armirotti A, Boss\u00f9 P, et al. Elevated plasma ceramide levels in post-menopausal women: a cross-sectional study. Aging (Albany NY). 2019;11(1):73\u201388.","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"1329_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jacl.2020.01.005","volume":"14","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Bonapace S, Lunardi G, Canali G, Dugo C, Vinco G. Ceramides and risk of major adverse cardiovascular events: a meta-analysis of longitudinal studies. J Clin Lipid. 2020;14(2):176\u201385.","journal-title":"J Clin Lipid"},{"issue":"18","key":"1329_CR33","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/eurheartj\/ehx205","volume":"38","author":"M Nicholls","year":"2017","unstructured":"Nicholls M. Plasma ceramides and cardiac risk. Eur Heart J. 2017;38(18):1359\u201360.","journal-title":"Eur Heart J"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01329-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-020-01329-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01329-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T23:20:49Z","timestamp":1624576849000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-020-01329-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1186\/s12944-020-01329-0","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Capital Medical University Affiliated Beijing Anzhen Hospital ethics committee has approved the study with the approval number 2017060X. All patients provided have submitted informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflicts of interest, financial issue or other issues are declared by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}